Lamotrigine Serum Level Monitoring for Adherence Assessment
Lamotrigine therapeutic drug monitoring (TDM) is not recommended as a routine tool for confirming adherence, as no clear therapeutic reference range has been established that reliably correlates with clinical efficacy. The evidence consistently shows that serum lamotrigine concentrations do not predict seizure control, making them unreliable for adherence verification 1.
Why Lamotrigine TDM Has Limited Value for Adherence
The fundamental problem is that no validated concentration-response relationship exists for lamotrigine. Research explicitly states that "clear relationships between concentration and pharmacologic response (either efficacy or toxicity) have not been demonstrated" 1. This means you cannot determine if a patient is taking their medication effectively just by looking at a serum level.
The Evidence Against Routine Monitoring
No efficacy correlation: A 2024 retrospective study of 549 concentrations from 259 epilepsy patients found that lamotrigine plasma concentration was not associated with seizure freedom (adjusted OR = 0.94; 95% CI, 0.85-1.04) 2
Only toxicity correlation exists: The same study found concentrations were positively associated with toxicity (OR = 1.11; 95% CI, 1.04-1.19), suggesting levels above 10 mg/L increase adverse effects without improving efficacy 2
Wide interindividual variability: Pediatric data shows lamotrigine concentrations ranging from 0.5 to 17.9 mg/L at therapeutic doses, with 22.6% of patients having trough levels below 2.5 mg/L despite adequate dosing 3
When TDM May Be Useful (Not for Adherence)
While not useful for adherence checking, lamotrigine levels have specific clinical applications:
1. Suspected Toxicity
Check levels when adverse effects occur (dizziness, diplopia, ataxia, somnolence). Levels above 10-12 mg/L correlate with increased toxicity risk 2.
2. Drug Interactions
- With valproate (inhibitor): Lamotrigine levels increase significantly. Dose-corrected concentrations show strong positive correlation (r=0.561, P<0.001) 4
- With enzyme inducers (carbamazepine, phenytoin, phenobarbital): Lamotrigine clearance increases, requiring higher doses 4, 5
3. Pharmacokinetic Changes
- Pregnancy: Lamotrigine clearance increases substantially
- Conversion between formulations: When switching from immediate-release to extended-release, trough concentrations remain similar at equivalent total daily doses 5
Practical Approach to Suspected Non-Adherence
Instead of relying on serum levels, use these strategies:
- Pill counts at clinic visits
- Pharmacy refill records to track prescription fills
- Direct observation when feasible
- Clinical response assessment (seizure frequency, mood stability)
- Therapeutic alliance building to encourage honest disclosure
If You Must Check a Level
If checking a level despite limited utility:
- Draw trough concentration (pre-dose, at steady state after 5-7 days on stable dose)
- Expect wide variability (2.5-15 mg/L is the traditional range, though evidence suggests 2.5-10 mg/L may be more appropriate) 2
- Do not use the level alone to determine adherence—a "low" level could reflect rapid metabolism, drug interactions, or true non-adherence
- A "therapeutic" level does not guarantee efficacy 1
Critical Caveat
The 2004 AAN/AES guidelines on antiepileptic drugs explicitly noted that "blood levels of [lamotrigine] were measured, but no therapeutic range was identified" in class I evidence trials 6. This remains true today—lamotrigine TDM for adherence assessment lacks evidence-based support and should not be routinely performed for this indication 1.